Maxim Group set a $3.00 price target on Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) in a research note issued to investors on Tuesday. The brokerage currently has a buy rating on the biotechnology company’s stock.

A number of other brokerages have also recently commented on ATNM. Roth Capital reissued a buy rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. HC Wainwright reissued a buy rating and issued a $6.00 price objective on shares of Actinium Pharmaceuticals in a research note on Monday, October 23rd. Finally, B. Riley began coverage on shares of Actinium Pharmaceuticals in a research note on Wednesday, December 6th. They issued a buy rating and a $2.75 price objective for the company.

Actinium Pharmaceuticals (NYSEAMERICAN ATNM) opened at $0.64 on Tuesday. Actinium Pharmaceuticals has a 52 week low of $0.54 and a 52 week high of $1.72.

TRADEMARK VIOLATION WARNING: This news story was first posted by Watch List News and is the property of of Watch List News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.watchlistnews.com/maxim-group-analysts-give-actinium-pharmaceuticals-atnm-a-3-00-price-target/1767009.html.

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc (Actinium) is a clinical-stage biopharmaceutical company engaged in developing cancer treatments. The Company is engaged in developing therapies for diseases using its alpha particle immunotherapy platform and other related technologies. The Company’s products include Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), and Iomab-B, an antibody-drug construct containing iodine 131 (I-131).

Receive News & Ratings for Actinium Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Actinium Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.